↓ Skip to main content

Cochrane Database of Systematic Reviews

Clonazepam add-on therapy for refractory epilepsy in adults and children

Overview of attention for article published in Cochrane database of systematic reviews, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

twitter
7 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
54 Mendeley
Title
Clonazepam add-on therapy for refractory epilepsy in adults and children
Published in
Cochrane database of systematic reviews, May 2018
DOI 10.1002/14651858.cd012253.pub2
Pubmed ID
Authors

Lin Song, Fang Liu, Yao Liu, Ruoqi Zhang, Huanhuan Ji, Yuntao Jia

Abstract

Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset or generalised onset epileptic seizures, when compared with placebo or another antiepileptic agent. We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). Double-blind randomised controlled studies of add-on clonazepam in people with refractory focal or generalised onset seizures, with a minimum treatment period of eight weeks. The studies could be of parallel or cross-over design. Two review authors independently selected studies for inclusion, extracted relevant data, and assessed trial quality. We contacted study authors for additional information. No double-blind randomised controlled trials met the inclusion criteria. There is no evidence from double-blind randomised controlled trials for or against the use of clonazepam as an add-on therapy for adults and children with refractory focal or generalised onset epileptic seizures.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 9 17%
Student > Master 8 15%
Student > Ph. D. Student 7 13%
Researcher 5 9%
Other 5 9%
Other 6 11%
Unknown 14 26%
Readers by discipline Count As %
Medicine and Dentistry 16 30%
Nursing and Health Professions 7 13%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Neuroscience 3 6%
Computer Science 1 2%
Other 4 7%
Unknown 19 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2018.
All research outputs
#4,240,984
of 17,140,695 outputs
Outputs from Cochrane database of systematic reviews
#6,671
of 11,626 outputs
Outputs of similar age
#84,040
of 284,409 outputs
Outputs of similar age from Cochrane database of systematic reviews
#125
of 176 outputs
Altmetric has tracked 17,140,695 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,626 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.7. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,409 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.